NASDAQ:BBNX Beta Bionics (BBNX) Stock Price, News & Analysis $13.35 -0.98 (-6.85%) Closing price 03:59 PM EasternExtended Trading$13.09 -0.26 (-1.91%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Beta Bionics Stock (NASDAQ:BBNX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Beta Bionics alerts:Sign Up Key Stats Today's Range$13.02▼$15.0750-Day Range$13.35▼$22.8152-Week Range$8.80▼$32.71Volume2.28 million shsAverage Volume1.17 million shsMarket Capitalization$725.73 millionP/E RatioN/ADividend YieldN/APrice Target$23.69Consensus RatingModerate Buy Company Overview Beta Bionics, Inc. develops medical technology for people with insulin-dependent diabetes. Its main product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to help manage blood glucose levels with less manual adjustment by users. The iLet system combines an insulin pump with dosing software that works with a continuous glucose monitor. Rather than requiring users to enter detailed insulin settings, it is initialized using the user’s body weight and adjusts insulin delivery based on glucose readings. The U.S. Food and Drug Administration cleared the system for use by people with type 1 diabetes ages six and older in 2023. Founded by researcher Edward Damiano, Beta Bionics developed the iLet through a multiyear effort to advance automated diabetes management. Sean Saint has served as the company’s chief executive officer. The company focuses on the U.S. diabetes-care market.AI Generated. May Contain Errors. Read More Beta Bionics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreBBNX MarketRank™: 3.32375478927 of 5 starsBeta Bionics scored higher than 66% of companies evaluated by MarketBeat, and ranked 198th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingBeta Bionics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 9 buy ratings, 4 hold ratings, and 1 sell rating.Upside PotentialBeta Bionics has a consensus price target of $23.69, representing about 77.5% upside from its current price of $13.35.Amount of Analyst CoverageBeta Bionics has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Beta Bionics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Beta Bionics are expected to decrease in the coming year, from ($2.04) to ($2.11) per share.Price to Book Value per Share RatioBeta Bionics has a P/B Ratio of 1.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted9.67% of the float of Beta Bionics has been sold short.Short Interest Ratio / Days to CoverBeta Bionics has a short interest ratio ("days to cover") of 3.94, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Beta Bionics has recently decreased by 27.99%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBeta Bionics does not currently pay a dividend.Dividend GrowthBeta Bionics does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.70 News SentimentBeta Bionics has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Beta Bionics this week, compared to 8 articles on an average week.Search Interest1 people have searched for BBNX on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Beta Bionics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Beta Bionics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,026,928.00 in company stock.Percentage Held by Insiders5.30% of the stock of Beta Bionics is held by insiders.Percentage Held by InstitutionsBeta Bionics has minimal institutional ownership at this time.Read more about Beta Bionics' insider trading history. Receive BBNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Beta Bionics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BBNX Stock News HeadlinesBeta Bionics (NASDAQ:BBNX) Insider Sells 775 Shares of StockNovember 19 at 7:37 AM | insidertrades.comSenseonics and Beta Bionics Launch Eversense® 365 and iLet® Bionic Pancreas IntegrationNovember 16 at 4:13 PM | globenewswire.comI'm handing you this stock todayElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.November 19 at 1:00 AM | Behind the Markets (Ad)Beta Bionics, Inc. (NASDAQ:BBNX) Stock Rated "Moderate Buy" by Sell-Side AnalystsNovember 16 at 2:01 AM | americanbankingnews.comBeta Bionics (NASDAQ:BBNX) CFO Sells 744 Shares of Company StockNovember 13, 2026 | insidertrades.comBeta bio: 3 key takeaways for long-term investorsNovember 9, 2026 | msn.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Beta Bionics, Inc. of Class Action Lawsuit and Upcoming Deadlines – BBNXNovember 3, 2026 | globenewswire.comBeta Bionics (NASDAQ:BBNX) Stock: Insider Mike Mensinger Sells 2,650 SharesOctober 30, 2026 | insidertrades.comSee More Headlines BBNX Stock Analysis - Frequently Asked Questions How have BBNX shares performed this year? Beta Bionics' stock was trading at $30.47 at the beginning of the year. Since then, BBNX stock has decreased by 56.2% and is now trading at $13.3480. How were Beta Bionics' earnings last quarter? Beta Bionics, Inc. (NASDAQ:BBNX) announced its quarterly earnings results on Tuesday, October, 27th. The company reported ($0.52) EPS for the quarter, topping analysts' consensus estimates of ($0.53) by $0.01. The business earned $35.51 million during the quarter. Beta Bionics had a negative trailing twelve-month return on equity of 27.33% and a negative net margin of 65.31%. Read the conference call transcript. When did Beta Bionics IPO? Beta Bionics (BBNX) raised $198 million in an IPO on Thursday, January 30th 2025. The company issued 12,000,000 shares at a price of $16.00-$17.00 per share. Who are Beta Bionics' major shareholders? Beta Bionics' top institutional shareholders include Soleus Capital Management L.P. (6.89%), State Street Corp (1.88%), Goldman Sachs Group Inc. (0.54%) and Jefferies Financial Group Inc. (0.17%). Insiders that own company stock include Hadley Harbor Aggre Wellington, Mike Mensinger, Steven Jon Russell, Stephen Feider, Mark Hopman, Adam Lezack and Christy Jones. View institutional ownership trends. How do I buy shares of Beta Bionics? Shares of BBNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings10/27/2026Today11/19/202638th Annual Healthcare Conference12/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 BBNX's financial health is in the Green zone, according to TradeSmith. BBNX has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:BBNX Previous SymbolNASDAQ:BBNX CIK1674632 Webwww.betabionics.com Phone(949) 427-7785FaxN/AEmployees423Year Founded2015Price Target and Rating Average Price Target for Beta Bionics$23.69 High Price Target$30.00 Low Price Target$16.00 Potential Upside/Downside+77.5%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($1.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$73.20 million Net Margins-65.31% Pretax Margin-65.31% Return on Equity-27.33% Return on Assets-24.28% Debt Debt-to-Equity RatioN/A Current Ratio8.92 Quick Ratio8.22 Sales & Book Value Annual Sales$100.25 million Price / Sales7.24 Cash FlowN/A Price / Cash FlowN/A Book Value$7.38 per share Price / Book1.81Miscellaneous Outstanding Shares54,370,000Free Float51,486,000Market Cap$725.73 million OptionableOptionable Beta3.44 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:BBNX) was last updated on 11/19/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beta Bionics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Beta Bionics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.